[go: up one dir, main page]

AR051888A1 - Anticuerpos frente al receptor alfa -1 de la il-13 y usos de los mismos - Google Patents

Anticuerpos frente al receptor alfa -1 de la il-13 y usos de los mismos

Info

Publication number
AR051888A1
AR051888A1 ARP060100010A ARP060100010A AR051888A1 AR 051888 A1 AR051888 A1 AR 051888A1 AR P060100010 A ARP060100010 A AR P060100010A AR P060100010 A ARP060100010 A AR P060100010A AR 051888 A1 AR051888 A1 AR 051888A1
Authority
AR
Argentina
Prior art keywords
alfa
receiver
same
antibodies against
antibody
Prior art date
Application number
ARP060100010A
Other languages
English (en)
Inventor
Jan Olaf Stracke
Kay-Gunnar Stubenrauch
De Winkel Jan Van
Vugt Martine Van
Sandra Vereecken-Verploegen
Josef Endl
Maria Elena Fuentes
Yvo Graus
Adelbert Grossmann
Sebastian Neumann
Paul Parren
Frank Rebers
Joerg Thomas Regula
Helmut E Schumacher
Stefan Seeber
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR051888A1 publication Critical patent/AR051888A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un anticuerpo con union a IL-13alfa1, inhibiendo la bioactividad de IL-12 y que contiene unas cadenas variables pesada y ligera, caracterizadas por que la secuencia de aminoácidos de la region variable de la cadena pesada CD3 de dicho anticuerpo es seleccionada a partir del grupo de secuencias de cadena pesada CD3 con Ns de ID SEC: 1, 3, 5, 7 o 9 es util en el tratamiento del asma y las enfermedades respiratorias.
ARP060100010A 2005-01-03 2006-01-03 Anticuerpos frente al receptor alfa -1 de la il-13 y usos de los mismos AR051888A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05000003 2005-01-03
EP05002229 2005-02-03

Publications (1)

Publication Number Publication Date
AR051888A1 true AR051888A1 (es) 2007-02-14

Family

ID=36199730

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100010A AR051888A1 (es) 2005-01-03 2006-01-03 Anticuerpos frente al receptor alfa -1 de la il-13 y usos de los mismos

Country Status (19)

Country Link
US (2) US7807158B2 (es)
EP (1) EP1836226B1 (es)
JP (1) JP5086098B2 (es)
KR (1) KR100934894B1 (es)
AR (1) AR051888A1 (es)
AT (1) ATE513855T1 (es)
AU (1) AU2006204480B2 (es)
BR (1) BRPI0606368A2 (es)
CA (1) CA2592614C (es)
CR (1) CR9209A (es)
IL (1) IL184205A0 (es)
MA (1) MA29226B1 (es)
MX (1) MX2007008128A (es)
NO (1) NO20073655L (es)
NZ (1) NZ556126A (es)
RU (1) RU2413736C2 (es)
SG (1) SG172504A1 (es)
TW (2) TWI306862B (es)
WO (1) WO2006072564A1 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US7605237B2 (en) 2006-10-02 2009-10-20 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
JP2010507366A (ja) * 2006-10-19 2010-03-11 メルク アンド カンパニー インコーポレイテッド インターロイキン−１３受容体α１の抗体アンタゴニスト
WO2008060814A2 (en) 2006-10-19 2008-05-22 Merck & Co., Inc. ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF
US7754213B2 (en) * 2006-10-19 2010-07-13 Merck & Co., Inc. High affinity antibody antagonists of interleukin-13 receptor alpha 1
CA2687837A1 (en) 2007-06-01 2008-12-04 F. Hoffmann-La Roche Ag Immunoglobulin purification
JP2010531340A (ja) * 2007-07-10 2010-09-24 エフ．ホフマン−ラ ロシュ アーゲー 新規処方物
TR201816045T4 (tr) 2007-10-12 2018-11-21 Hoffmann La Roche Birden fazla nükleik asitten protein ekspresyonu.
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
KR101187627B1 (ko) 2007-12-15 2012-10-09 에프. 호프만-라 로슈 아게 식별 검정법
BRPI1006448B1 (pt) * 2009-03-25 2021-08-17 Genentech, Inc Anticorpo antagonista anti-fgfr3, anticorpo monoclonal, polinucleotídeo, vetor, micro­organismo transgênico, método para produção de um anticorpo anti-fgfr3, formulação farmacêutica e usos do anticorpo antagonista anti-fgfr3
EP2431463A4 (en) * 2009-05-13 2012-12-26 Shionogi & Co TESTS FOR VISCERAL ADIPOSITAS AND ITS USE
US9289699B2 (en) 2009-07-30 2016-03-22 Hoffmann-La Roche Inc. Moveable chromatography column separator
WO2011038894A1 (en) 2009-10-01 2011-04-07 F. Hoffmann-La Roche Ag Protein a chromatography
PL2483305T3 (pl) 2009-10-01 2017-03-31 F.Hoffmann-La Roche Ag Wieloetapowa końcowa filtracja immunoglobuliny
MX337290B (es) 2009-10-19 2016-02-24 Hoffmann La Roche Anticuerpos anti igg reactivos no cruzados.
EP2516460B1 (en) 2009-12-22 2015-03-04 F.Hoffmann-La Roche Ag Sequence dependent aggregation
MX360347B (es) 2010-08-17 2018-10-30 F Hoffmann La Roche Ag Star Anticuerpo anti-inmunoglobulina g1 humana.
CN103339502B (zh) 2011-02-02 2016-02-17 霍夫曼-拉罗奇有限公司 色谱柱支撑体
CN103702682A (zh) 2011-04-21 2014-04-02 科罗拉多州立大学董事会法人团体 治疗视神经脊髓炎的组合物和方法
KR102502640B1 (ko) 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
WO2015000865A1 (en) 2013-07-04 2015-01-08 F. Hoffmann-La Roche Ag Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
AU2014368449C1 (en) 2013-12-20 2021-05-06 Intervet International B.V. Canine antibodies with modified CH2-CH3 sequences
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CN106062000B (zh) 2014-02-28 2021-05-28 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗皮肤感染的方法
PT3613432T (pt) 2014-05-07 2025-10-29 Regeneron Pharma Métodos para tratar a polipose nasal através da administração de um antagonista de il-4r
ES2853823T3 (es) 2014-09-30 2021-09-17 Intervet Int Bv Anticuerpos de PD-L1 que se unen a PD-L1 canino
IL303337B1 (en) 2014-11-14 2025-10-01 Regeneron Pharma Methods for treating chronic sinusitis with nasal polyps by adding an IL-4–R4 antagonist
WO2017032611A1 (en) * 2015-08-21 2017-03-02 F. Hoffmann-La Roche Ag Method for the reduction of host cell proteins in affinity chromatography
MX388197B (es) 2015-08-21 2025-03-19 Hoffmann La Roche Método para la reducción de proteínas de células hospederas en cromatografía de afinidad.
DK3390451T3 (da) 2015-12-18 2025-03-17 Intervet Int Bv Kaniniserede humane antistoffer mod il-4r-alpha hos mennesker og hunde
US11091556B2 (en) 2015-12-18 2021-08-17 Intervet Inc. Caninized human antibodies to human IL-4R alpha
WO2018011405A1 (en) * 2016-07-15 2018-01-18 Universität Zürich Il-13ralpha1 antibodies for use in treatment of atopic inflammation, sepsis and neutropenia
ES2994774T3 (en) 2016-09-01 2025-01-31 Regeneron Pharma Methods for preventing or treating allergy by administering an il-4r antagonist
JOP20190009A1 (ar) 2016-09-21 2019-01-27 Alx Oncology Inc أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
AU2017370937A1 (en) 2016-12-07 2019-05-30 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
MX2020004467A (es) 2017-10-30 2020-10-22 Sanofi Biotechnology Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
AU2019240111A1 (en) 2018-03-21 2020-09-17 ALX Oncology Inc. Antibodies against signal-regulatory protein alpha and methods of use
CN120227453A (zh) 2018-05-13 2025-07-01 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
AU2020247175A1 (en) 2019-03-26 2021-10-14 Aslan Pharmaceuticals Pte Ltd Treatment employing anti-IL-13R antibody or binding fragment thereof
US12398212B2 (en) 2019-07-16 2025-08-26 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
KR20220044563A (ko) 2019-08-05 2022-04-08 리제너론 파아마슈티컬스, 인크. Il-4r 길항제를 투여함에 의해 아토피 피부염을 치료하기 위한 방법
SG11202113312VA (en) 2019-08-05 2021-12-30 Regeneron Pharma Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2022186772A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2022186773A1 (en) 2021-03-01 2022-09-09 Aslan Pharmaceuticals Pte Ltd TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
WO2023048651A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd Method for treatment of moderate to severe atoptic dematitis
WO2023048650A1 (en) 2021-09-27 2023-03-30 Aslan Pharmaceuticals Pte Ltd TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
WO2023075702A1 (en) 2021-10-29 2023-05-04 Aslan Pharmaceuticals Pte Ltd Anti-il-13r antibody formulation
JP2025529908A (ja) 2022-08-26 2025-09-09 アスラン ファーマシューティカルズ ピーティーイー リミテッド 高濃度抗ｉｌ１３ｒ抗体製剤
EP4594352A1 (en) 2022-09-06 2025-08-06 ASLAN Pharmaceuticals Pte Ltd Treatment for sleep loss or sleep disturbance in patients with dermatitis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5614191A (en) 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
CA2238080C (en) 1995-10-23 2012-03-13 Amrad Operations Pty. Ltd. A novel haemopoietin receptor and genetic sequences encoding same
US5843659A (en) * 1996-03-21 1998-12-01 Apoptosis Technology, Inc. Apoptosis gene EI24, compositions, and methods of use
AU2002361122A1 (en) * 2001-11-27 2003-06-10 Mochida Pharmaceutical Co., Ltd. ANTI-IL13 RECEPTOR Alpha1 NEUTRALIZING ANTIBODY
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
EP1576013A4 (en) * 2002-03-22 2008-08-13 Amrad Operations Pty Ltd MONOCLONAL ANTIBODY AGAINST THE INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13RA1)
WO2004081186A2 (en) * 2003-03-10 2004-09-23 Applera Corporation Single nucleotide polymorphisms associated with stenosis, methods of detection and uses thereof
TWI385180B (zh) * 2003-07-15 2013-02-11 安美基公司 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體

Also Published As

Publication number Publication date
CR9209A (es) 2007-08-28
RU2413736C2 (ru) 2011-03-10
JP5086098B2 (ja) 2012-11-28
EP1836226A1 (en) 2007-09-26
TW200635945A (en) 2006-10-16
US20110086026A1 (en) 2011-04-14
MX2007008128A (es) 2007-07-20
ATE513855T1 (de) 2011-07-15
KR100934894B1 (ko) 2010-01-07
AU2006204480B2 (en) 2011-06-09
AU2006204480A1 (en) 2006-07-13
KR20070091180A (ko) 2007-09-07
EP1836226B1 (en) 2011-06-22
RU2007129676A (ru) 2009-02-10
CA2592614A1 (en) 2006-07-13
TW200902555A (en) 2009-01-16
BRPI0606368A2 (pt) 2009-06-23
MA29226B1 (fr) 2008-02-01
SG172504A1 (en) 2011-07-28
CA2592614C (en) 2015-04-14
IL184205A0 (en) 2007-10-31
JP2008526187A (ja) 2008-07-24
NZ556126A (en) 2008-09-26
WO2006072564A1 (en) 2006-07-13
US7807158B2 (en) 2010-10-05
NO20073655L (no) 2007-08-02
US20060263356A1 (en) 2006-11-23
TWI306862B (en) 2009-03-01
HK1112006A1 (en) 2008-08-22

Similar Documents

Publication Publication Date Title
AR051888A1 (es) Anticuerpos frente al receptor alfa -1 de la il-13 y usos de los mismos
CO6220978A2 (es) Anticuerpos dirigidos a proteina-1 quimio-tactica de monocitos (mcp-1)y sus usos
PE20141166A1 (es) Anticuerpos anti-angptl3 y usos de los mismos
ES2689746T3 (es) Anticuerpos monoclonales contra la claudina-18 para el tratamiento de cáncer
ATE403680T1 (de) Herstellung tetravalenter antikörper
DE60320009D1 (de) Transplant-Akzeptanz induzierende Zellen monocytären ursprungs, sowie deren Herstellung und Verwendung
PE20080035A1 (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
EA200800812A1 (ru) Композиции антитела против cd3
AR075790A2 (es) Anticuerpos anti -ngf humanos neutralizantes como inhibidores selectivos de la via de ngf (factor de crecimiento neural)
PE20081899A1 (es) Anticuerpos anti-ige
UA106607C2 (uk) Білки специфічного зв'язування і їх застосування
PE20121361A1 (es) Antagonistas de pcsk9
ECSP14011269A (es) Formulaciones de anticuerpos y proteínas de alta concentración
NZ597676A (en) Crystalline anti-hTNFalpha antibodies
CO5700152A1 (es) Nuevos anticuerpos anti-igf-ir y sus usos
PE20061395A1 (es) Anticuerpos contra miostatina
AR086272A2 (es) Anticuerpos anti-factor d humanizados y sus usos
PE20080036A1 (es) Anticuerpos humanos para la interleucina-13 (il13)
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
GEP20104991B (en) Antibodies that bind interleukin-4 receptor
PE20081214A1 (es) Anticuerpo especifico prlr y sus usos
TW200745164A (en) Gene recombination antibodies composition
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20060376A1 (es) ANTICUERPO MONOCLONAL HUMANIZADO O QUIMERICO COMO INHIBIDOR DE hIL-3
PE20080846A1 (es) Composiciones y metodos relacionados con los anticuerpos receptores de glucagon

Legal Events

Date Code Title Description
FB Suspension of granting procedure